Hypersensitivity Reactions Secondary to Dupilumab in Two Patients with Moderate to Severe Atopic Dermatitis

Main Article Content

Raina Bembry
Navid Malakouti
Mary Maiberger


dupilumab, biologics, atopic dermatitis, drug reaction, hypersensitivity


Dupilumab is a human monoclonal IgG4 antibody that is widely used to treat atopic dermatitis. Dupilumab was recently FDA approved to treat moderate to severe atopic dermatitis. Here we decribe two cases of patients with moderate to severe atopic dermatitis who developed an acute hypersensitivity reaction within hours of their second dose of dupilumab.


Eichenfeld LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis. Journal of the American Academy of Dermatology, 2014;71(1):116-132. do:10.1016/j.jaad.2014.03.023.

Bieber T. Atopic Dermatitis, Annals of Dermatology. 2019;22(2):125. doi:10.5021/ad.2010.22.2.125.

Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis. Journal of the American Academy of Dermatology. 2014;71(2):327-349. doi.10.1016/j.jaad.2014.03.030.

Dreme AM, Romanelli M, Chiricozzi A. Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy. Drug Design, Development and Therapy. 2017; Volume 11:1473-1480. doi:10.2147/dddt.s113192.

Mansouri Y, Guttman-Yassky E. Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad an Targeted Therapies. Journal of Clinical Medicine. 2015;4(5):858-873. doi:10.3390/jcm4050858.

Renert-Yuval Y, Guttman-Yassky E. Systemic therapies in atopic dermatitis: The pipeline. Clinics in Dermatology. 2017;35(4):387-397. doi: 10.1016/j.clindermatol.2017.03.012.

Simpson EL, Bieber T, Guttman-Yassky E, et al, Two Phase 3 Trials of Dupilumab verses Placebo in Atopic Dermatitis. New England Journal of Medicine. 2016;375(24):2335-2348. doi:10,1056/nejmoa1610020.

Dupixent (dupilumab) [Package Insert]. Sanofi Biotechnology (Bridgewater, NJ) and Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)

Zaki S. Advere drug reaction and causality assessment scales. Lung India. 2011;28(2):152. doi:10.4103/0970-2113.80343.

Davis JD, Bansal A, Hassman D, et al. Evaluation of Potential Disease-Mediated Drug-Drug Interaction in Patients with Moderate-to Severe Atopic Dermatitis Receiving Dupilumab. Clinical Pharmacology & Therapeutics. February 2018. doi:10.1002/cpt.1058.